A phase I open-label, two period, single center study to assess the effect of 600 mg daily oral dose of rifampin (CYP3A4 inducer) on the pharmacokinetics of a single 400 mg oral dose of nilotinib in healthy subjects.

Trial Profile

A phase I open-label, two period, single center study to assess the effect of 600 mg daily oral dose of rifampin (CYP3A4 inducer) on the pharmacokinetics of a single 400 mg oral dose of nilotinib in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2010

At a glance

  • Drugs Nilotinib; Rifampicin
  • Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Malignant melanoma; Tuberculosis
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 20 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top